Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000131.xml
Synfacts 2020; 16(11): 1353
DOI: 10.1055/s-0040-1706368
DOI: 10.1055/s-0040-1706368
Chemistry in Medicine and Biology
A PROTAC for KRAS G12C Degradation
Bond MJ,
Chu L,
Nalawansha DA,
Li K,
Crews CM.
*
Yale University, New Haven, USA
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs.
ACS Cent. Sci. 2020;
6: 1367-1375
DOI: 10.1021/acscentsci.0c00411
Targeted Degradation of Oncogenic KRASG12C by VHL-Recruiting PROTACs.
ACS Cent. Sci. 2020;
6: 1367-1375
DOI: 10.1021/acscentsci.0c00411
Significance
KRas is one of the most promising cancer drug targets, but targeting it has been a challenge. Crews and co-workers employed covalent KRas G12C inhibitors for the development of PROTACS that allowed for its targeted degradation.
#
Comment
A solvent-exposed site in the clinical drug candidate MRTX849 was identified and used for conjugation to a linker and a VHL ligand to yield the PROTAC LC-2.
#
#
Publication History
Article published online:
20 October 2020
© 2020. Thieme. All rights reserved
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany